Project Updates

Credit: BIOVECTRA

Location: Charlottetown, Prince Edward Island, Canada 
Project type: mRNA Vaccine and Biomanufacturing Centre 
Announced: November 2021 
Construction Started: April 2022

BIOVECTRA, a biotech and pharmaceutical company, is building a new facility to produce and manufacture messenger ribonucleic acid (mRNA) vaccines and therapeutics at its Charlottetown campus in Canada.

Credit: AGC Biologics

Location: Heidelberg, Germany 
Project type: Manufacturing Facility Expansion 
Announced: September 2021 
Completion: October 2023 

AGC Biologics (AGC), a contract development and manufacturing organisation (CDMO) based in the US, has expanded its facility in Heidelberg, Germany, to increase its plasmid DNA (pDNA) and messenger RNA (mRNA) manufacturing capabilities.

Credit: Novo Nordisk

Location: Kalundborg, Denmark 
Project type: Active pharmaceutical ingredients (API) manufacturing facility 
Estimated Investment: More than DKr42bn ($6bn) 
Area: 170,000m²

Novo Nordisk, a pharmaceutical company based in Denmark, announced plans in November 2023 to expand its existing manufacturing capacity by building a new active pharmaceutical ingredients (API) facility in Kalundborg, Denmark.